Francesco Ferrara | Pharmacist | Innovative Research Award

Published on by Research Awards

Innovative Research Award

Francesco Ferrara – ASL Napoli 3 SUD, Italy
Francesco Ferrara
AffiliationASL Napoli 3 SUD
CountryItaly
Scopus ID59464334600
Documents1546
Citations2176
h-index27
Subject AreaPharmacist
EventInternational Research Awards
ORCID0000-0001-9298-6783

Francesco Ferrara is an Italian hospital pharmacist and researcher affiliated with ASL Napoli 3 SUD. His academic profile demonstrates extensive contributions to pharmacology, clinical pharmacy, healthcare governance, and therapeutic innovation. Through a substantial publication record and active international collaboration, he has contributed to evidence-based healthcare practices and multidisciplinary medical research.[1]

Abstract

This article evaluates the scholarly profile of Francesco Ferrara in relation to the Innovative Research Award. His research activities encompass pharmacology, healthcare management, antimicrobial resistance, chronic disease treatment, and pharmaceutical policy. The combination of publication productivity, citation influence, and interdisciplinary engagement highlights a sustained commitment to advancing healthcare knowledge and clinical practice.[1]

Keywords

Pharmacology, Clinical Pharmacy, Healthcare Governance, Drug Policy, Therapeutic Innovation, Antimicrobial Resistance, Pharmaceutical Research.

Introduction

Modern healthcare requires researchers capable of integrating clinical evidence, pharmaceutical management, and public health priorities. Francesco Ferrara has developed a multidisciplinary portfolio addressing therapeutic effectiveness, healthcare sustainability, and emerging treatment strategies. His work reflects contemporary priorities in patient-centered care and pharmaceutical innovation.[2]

Research Profile

Ferrara serves within the Italian Health Service and has accumulated professional experience across multiple healthcare institutions. His expertise includes clinical pharmacy, pharmacoeconomics, healthcare technology assessment, and pharmaceutical governance. The researcher maintains active participation in scientific publishing and peer-review activities across internationally recognized journals.[1]

Research Contributions

Key contributions include investigations into antimicrobial resistance, biosimilar medicines, chronic disease management, neurological disorders, dermatological therapies, and healthcare expenditure analysis. His research frequently combines clinical relevance with policy implications, supporting informed decision-making in healthcare systems and pharmaceutical practice.[3]

Publications

Publications

Francesco Ferrara has authored and co-authored an extensive portfolio of scholarly publications spanning pharmacology, clinical pharmacy, antimicrobial resistance, chronic disease management, dermatology, neurology, cardiovascular medicine, and healthcare governance. His research has appeared in internationally recognized journals including Inflammopharmacology, European Journal of Clinical Pharmacology, Pharmaceuticals, Antibodies, and Hospital Pharmacy. Through collaborations with multidisciplinary research teams, he has contributed to studies addressing therapeutic innovation, drug utilization, public health challenges, and evidence-based healthcare policies. The breadth and consistency of his publication record demonstrate sustained scientific productivity and a commitment to advancing pharmaceutical and clinical research across diverse healthcare settings.[2][3]

Research Impact

With more than two thousand citations and a substantial h-index, Ferrara’s scholarly output demonstrates measurable academic influence. His studies contribute to clinical practice, healthcare policy development, and pharmaceutical governance. The broad thematic coverage of his work illustrates a capacity to address both specialized and system-level healthcare challenges.[1]

Award Suitability

The Innovative Research Award recognizes individuals who demonstrate originality, sustained scholarly productivity, and meaningful research outcomes. Ferrara’s record of publications, international collaborations, and healthcare-focused investigations aligns with these criteria. His contributions support innovation in pharmacological science and evidence-based healthcare management.[4]

Conclusion

Francesco Ferrara has established a notable academic profile through sustained research activity, clinical expertise, and interdisciplinary collaboration. His contributions to pharmacology and healthcare policy provide practical and scholarly value. These achievements support his recognition as a strong candidate for the Innovative Research Award.[5]

References

    1. ORCID. (2026). Francesco Ferrara (ORCID iD: 0000-0001-9298-6783). ORCID Registry.
      https://orcid.org/0000-0001-9298-6783
    2. Ferrara, F., De Berardinis, F., Scognamiglio, M., & Zovi, A. (2026). The shifting paradigm of monoclonal antibodies in COVID-19 management: From early triumphs to viral resistance and future perspectives. Antibodies, 15(3), Article 48.
      https://doi.org/10.3390/antib15030048
    3. Ferrara, F. (2026). Therapeutic update on alopecia areata: A critical review of standard and emerging targeted therapies. Inflammopharmacology.
      https://doi.org/10.1007/s10787-026-02273-8
    4. Ferrara, F., Martellone, L., Vaccaro, M., Coluccia, A., Scognamiglio, M., Langella, R., Zovi, A., & Polito, G. (2025). Real-life impact of cefiderocol in carbapenem-resistant Acinetobacter baumannii infections (CRAb): A narrative review. European Journal of Clinical Pharmacology.
      https://doi.org/10.1007/s00228-025-03866-y
    5. Elsevier. (2026). Scopus Author Profile: Francesco Ferrara (Author ID: 59464334600). Scopus Preview.
      https://www.scopus.com/authid/detail.uri?authorId=59464334600

EMAD MOLAEI | Pharmaceutical Science | Young Scientist Award

Published on by Research Awards

Dr. EMAD MOLAEI | Pharmaceutical Science | Young Scientist Award

Clinical pharmacy resident at Tehran University of Medical Sciences, Iran.

Dr. Emad Molaei is a PGY3 Pharmacotherapy Resident at Tehran University of Medical Sciences/Imam Khomeini Hospital Complex. With a PharmD from Mashhad University of Medical Sciences and a current residency in Pharmacotherapy, he has a strong foundation in clinical pharmacy. His research focuses on nephroprotective activity, cardiovascular diseases, and COVID-19 treatments, with several first-author publications in renowned journals. Dr. Molaei’s professional experience includes roles as a community pharmacist, medication consultant, and pharmacotherapy interventionist in various hospitals. He is also the Founder and Director of the R&D Department at Daneshafza Razi Pharmaceutical Company. Recognized for his academic excellence, he has received multiple awards and honors, including being the top-ranked graduate and outstanding student at each academic level. Dr. Molaei is skilled in data analysis, scientific writing, and project management, contributing significantly to his field.

Professional Profiles:

Education 🎓

🎓 Emad Molaei is currently pursuing his Pharmacotherapy (Clinical Pharmacy) residency at the School of Pharmacy, Tehran University of Medical Sciences (TUMS), since September 2021. He completed his Pharm-D at the School of Pharmacy, Mashhad University of Medical Sciences (MUMS) in September 2021, achieving a commendable total average of 18.00. Prior to that, he earned his Diploma of Science from the Gifted Program in the National Organization for Development, with an impressive total average of 19.46 in September 2015.

Professional Experience

👨‍⚕️ Emad Molaei’s professional journey includes his current role as a PGY3 Pharmacotherapy Resident at Tehran University of Medical Sciences / Imam Khomeini Hospital Complex. He has extensive clinical experience as a Community Pharmacist at 13-Aban TUMS Community Chain Pharmacy in Tehran and Razavi Pharmaceutical Service Institute in Mashhad. Additionally, he has served as a Medication Consultant at the Drug and Poison Information Center (DPIC) in Tehran and has been involved in pharmacotherapy interventions at several hospitals, including Imam Khomeini, Shariati, Sina, and Roozbeh Hospitals in Tehran. Emad also has experience working in the satellite pharmacy of the critical care department at Sina Hospital and initiated activities in the clean room dedicated to cytotoxic drug production at the Cancer Institute, Imam Khomeini Hospital Complex. Beyond his clinical roles, he has contributed as a Research Assistant and Teacher Assistant in Pharmacotherapy, Pharmacology, and Toxicology.

Research Interest

🔬 Emad Molaei’s research interests span across various aspects of clinical pharmacy and pharmacotherapy. He is particularly focused on the nephroprotective activity of natural products against chemical toxicants and the role of the Nrf2/ARE signaling pathway. Emad also investigates the therapeutic potential of Resolvin D1 in Acute Respiratory Distress Syndrome and explores emerging therapeutic targets for cardiovascular diseases, including the LKB1 pathway and the Mas receptor. Additionally, he is involved in clinical studies evaluating the efficacy and safety of treatments for burn patients, such as silver sulfadiazine 1%-cerium nitrate 2.2% cream. Emad’s work also extends to the treatment of COVID-19 with Remdesivir in special populations, showcasing his commitment to addressing critical health issues through innovative research.

Award and Honors

🏆 Emad Molaei has received numerous awards and honors throughout his academic and professional career. He was recognized as the most outstanding student at each academic level and graduated as the top-ranked student from the Mashhad Faculty of Pharmacy. Emad also achieved the highest rank in the pharmacy specialty examination and is a member of the Brilliant Academic Talent Program. His presentation skills have been acknowledged with the best poster award at the 12th subspecialty congress of Iranian burn physicians. Emad’s dedication to excellence is further demonstrated by his active membership in various professional organizations and his role as the Founder and Director of the R&D Department at Daneshafza Razi Pharmaceutical Company.

Research Skills

🧪 Emad Molaei possesses a robust set of research skills. He is proficient in data analysis using software such as SPSS, GraphPad Prism, and Sigma Plot. His scientific writing abilities are well-honed, and he is adept with EndNote and Microsoft Office tools. Emad’s project management skills are complemented by his experience as a Research Assistant and Teacher Assistant in Pharmacotherapy, Pharmacology, and Toxicology. His clinical research experience includes participation in multiple clinical trials and studies, showcasing his ability to handle complex research projects effectively.

Publications by Emad Molaei

  1. Remdesivir: Treatment of COVID-19 in Special Populations
    • Authors: Molaei, E., Molaei, A., Hayes, A.W., Karimi, G.
    • Journal: Naunyn-Schmiedeberg’s Archives of Pharmacology
    • Year: 2024
    • Citations: 1
  2. Mas Receptor: A Potential Strategy in the Management of Ischemic Cardiovascular Diseases
    • Authors: Molaei, A., Molaei, E., Hayes, A.W., Karimi, G.
    • Journal: Cell Cycle
    • Year: 2023
    • Citations: 5
  3. LKB1: An Emerging Therapeutic Target for Cardiovascular Diseases
    • Authors: Molaei, A., Molaei, E., Sadeghnia, H., Hayes, A.W., Karimi, G.
    • Journal: Life Sciences
    • Year: 2022
    • Citations: 13
  4. Resolvin D1: Therapeutic Target in Acute Respiratory Distress Syndrome
    • Authors: Molaei, E., Molaei, A., Hayes, A.W., Karimi, G.
    • Journal: European Journal of Pharmacology
    • Year: 2021
    • Citations: 18
  5. Nephroprotective Activity of Natural Products Against Chemical Toxicants: The Role of Nrf2/ARE Signaling Pathway
    • Authors: Molaei, E., Molaei, A., Abedi, F., Hayes, A.W., Karimi, G.
    • Journal: Food Science and Nutrition
    • Year: 2021
    • Citations: 23